PFIZER INC
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.
| Pfizer Inc. | ||
| Dated: February 22, 2024 | By: | /S/ MARGARET M. MADDEN |
|---|---|---|
| Margaret M. MaddenSenior Vice President and Corporate SecretaryChief Governance Counsel | ||
We, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, our true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Under the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities and on the date indicated.
| Signature | Title | Date | |
|---|---|---|---|
| /S/ ALBERT BOURLAAlbert Bourla | Chairman, Chief Executive Officer and Director(Principal Executive Officer) | February 20, 2024 | |
| /S/ DAVID M. DENTONDavid M. Denton | Chief Financial Officer, Executive Vice President(Principal Financial Officer) | February 20, 2024 | |
| /S/ JENNIFER B. DAMICOJennifer B. Damico | Senior Vice President and Controller(Principal Accounting Officer) | February 20, 2024 | |
| /S/ RONALD E. BLAYLOCKRonald E. Blaylock | Director | February 21, 2024 | |
| /S/ SUSAN DESMOND-HELLMANNSusan Desmond-Hellmann | Director | February 21, 2024 | |
| /S/ JOSEPH J. ECHEVARRIAJoseph J. Echevarria | Director | February 20, 2024 | |
| /S/ SCOTT GOTTLIEBScott Gottlieb | Director | February 21, 2024 | |
| /S/ HELEN H. HOBBSHelen H. Hobbs | Director | February 20, 2024 | |
| /S/ SUSAN HOCKFIELDSusan Hockfield | Director | February 20, 2024 | |
| /S/ DAN R. LITTMANDan R. Littman | Director | February 20, 2024 | |
| /S/ SHANTANU NARAYENShantanu Narayen | Director | February 20, 2024 | |
| /S/ SUZANNE NORA JOHNSONSuzanne Nora Johnson | Director | February 20, 2024 | |
| /S/ JAMES QUINCEYJames Quincey | Director | February 21, 2024 | |
| /S/ JAMES C. SMITHJames C. Smith | Director | February 20, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.